Market Place
Sourcing Support
Allogene Therapeutics Reveals ALLO-329, Pre-Clinical Data
15 Apr 2026 //
FIRSTWORD PHARMA
Cellectis` Cema-Cel Shows Strength In Pivotal Trial Interim Data
13 Apr 2026 //
GLOBENEWSWIRE
Allogene CAR T Shows Promise In Clearing Residual Lymphoma
13 Apr 2026 //
BIOSPACE
Allogene Therapeutics To Release Interim Data On Cema-Cel
10 Apr 2026 //
GLOBENEWSWIRE
Allogene Therapeutics Reveals 2025 Financials And Business Update
12 Mar 2026 //
GLOBENEWSWIRE
Allogene Reports Q4 2025 Financial Results, Business Update
02 Mar 2026 //
GLOBENEWSWIRE
Allogene Therapeutics To Present At Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
Allogene Positions 2026 as a Program-Defining Year for Scalabl
08 Jan 2026 //
GLOBENEWSWIRE
Allogene Therapeutics To Participate In Investor Conferences
10 Nov 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Unveils Q3 2025 Financials & Business
06 Nov 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Presents ALPHA3 Trial Poster at ASH Meeting
03 Nov 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Release Q3 2025 Financials and Business
30 Oct 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Q2 2025 Financial Results and Update
13 Aug 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Report Q2 2025 Financial Result
06 Aug 2025 //
GLOBENEWSWIRE
Allogene Scraps Immunosuppressive Antibody Post Patient Death
05 Aug 2025 //
BIOSPACE
Allogene Scraps Immunosuppressive Antibody Post Patient Death
04 Aug 2025 //
BIOSPACE
Allogene Reports Patient Death, Discontinues CAR-T Pivotal Trial
02 Aug 2025 //
FIERCE BIOTECH
Allogene advances FC lymphodepletion in ALPHA3 trial
01 Aug 2025 //
GLOBENEWSWIRE
Allogene Therapeutics Updates Phase 1 Data on ALLO-316 at ASCO
01 Jun 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Join Investor Conferences
23 May 2025 //
GLOBENEWSWIRE
Allogene ASCO 2025 Data To Highlight ALLO-316 And Cema-Cel
22 May 2025 //
GLOBENEWSWIRE
Allogene lays off 28% of staff to save cash amid program delays
14 May 2025 //
FIERCE BIOTECH
Allogene Therapeutics Reports Q1 2025 Financial Results
13 May 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Report Q1 2025 Results and Update
06 May 2025 //
GLOBENEWSWIRE
Allogene to Present ALLO-316 Kidney Cancer Results at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
Allogene Gets 3 FDA Fast Tracks for ALLO-329 in Autoimmune
07 Apr 2025 //
GLOBENEWSWIRE
Allogene To Report Q4 & FY24 Results, Business Update
03 Mar 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Join March Investor Conference
26 Feb 2025 //
GLOBENEWSWIRE
Allogene Publishe Durable Data from Trials in Large B-Cell Lymphoma
13 Feb 2025 //
GLOBENEWSWIRE
Allogene Announces Participation in Feb Investor Conferences
04 Feb 2025 //
GLOBENEWSWIRE
Allogene Announces Benjamin as Senior Vice President & CTO
29 Jan 2025 //
GLOBENEWSWIRE
Allogene FDA IND Clearance For ALLO-329 In Autoimmune Diseases
28 Jan 2025 //
GLOBENEWSWIRE
Allogene Therapeutics to Present at J.P. Morgan Healthcare Conf.
16 Dec 2024 //
GLOBENEWSWIRE
Allogene Acknowledges Passing of Founding Board Member David
12 Dec 2024 //
GLOBENEWSWIRE
Allogene Announces December Investor Conference Participation
19 Nov 2024 //
GLOBENEWSWIRE
Allogene Presents ALLO-329 Data for Autoimmune Disease at ACR
18 Nov 2024 //
GLOBENEWSWIRE
Allogene abandons leukemia CAR-T plans after Breyanzi approval
14 Nov 2024 //
FIERCE BIOTECH
Allogene links solid tumor CAR-T to responses, deaths in phase 1
08 Nov 2024 //
FIERCE BIOTECH
Allogene Reports Phase 1 Data on ALLO-316 in Renal Cancer at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Allogene Presents ALLO-316 Data in Renal Cell Carcinoma at IKCS
05 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Participate in Nov Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Report Q3 2024 Results & Update
30 Oct 2024 //
GLOBENEWSWIRE
Allogene Receives FDA RMAT Designation for ALLO-316 in RCC
29 Oct 2024 //
GLOBENEWSWIRE
Allogene participate Goldman Sachs Cell Therapy Day Conference
30 Sep 2024 //
GLOBENEWSWIRE
Allogene To Present Data On ALLO-329 At ACR Convergence
26 Sep 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08 Aug 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Q2 2024 Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Allogene Therapeutics and Arbor Biotechnologies Announce Agreement
12 Mar 2024 //
GLOBENEWSWIRE
Allogene to ramp up enrolment in Phase II CAR-T trials
16 Jun 2023 //
CLINICAL TRIALS ARENA
Ex-Metacrine chief Preston Klassen recharges at microRNA biotech
16 Jun 2023 //
ENDPTS
Allogene Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma
03 Jun 2023 //
GLOBENEWSWIRE
Allogene Announces Encore Presentation of PI Data from the ALLO-501/501A Trials
11 May 2023 //
GLOBENEWSWIRE
Allogene Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials
26 Apr 2023 //
GLOBENEWSWIRE
Allogene Announces Oral Presentation of Phase 1 Data on ALLO-316
14 Mar 2023 //
GLOBENEWSWIRE
Allogene Announces Publication from PI UNIVERSAL Study of ALLO-715
24 Jan 2023 //
GLOBENEWSWIRE
